Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Dublin, Nov. 18, 2016 -- Research and Markets has announced the addition of the "Sickle Cell Anemia Drugs Price Analysis and Strategies - 2016" report to their offering.
Sickle Cell Anemia Drugs Price Analysis and Strategies 2016, provides drug pricing data and benchmarks in the global Sickle Cell Anemia market.
The research answers the following questions:
- What are the key drugs marketed for Sickle Cell Anemia and their clinical attributes? How are they positioned in the Global Sickle Cell Anemia market?
- What are the unit prices and annual treatment cost for Sickle Cell Anemia therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
- What are the unmet needs in the global Sickle Cell Anemia drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Sickle Cell Anemia?
Research Scope:
- Treatment Options - Identify key drugs marketed and prescribed for Sickle Cell Anemia including trade name, molecule name, and company
- Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Sickle Cell Anemia
- Market Positioning - Identify how drugs are clinically and commercially positioned in the global Sickle Cell Anemia market
- Sickle Cell Anemia Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed
- Find out how the price advanced from 2012 and forecast to 2021
- Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape
- Sickle Cell Anemia New Drug Pricing - Identify the effective pricing strategy for a new drug launch
Key Topics Covered:
1. Treatment Options
2. Drugs Clinical Attributes
3. Drugs Market Positioning
4. Drugs Price Analysis
5. Drugs Price Benchmarks
6. Drug Pricing & Reimbursement Landscape
7. Drugs Price Forecast
8. Market Unmet Needs
9. New Drug Pricing
For more information about this report visit http://www.researchandmarkets.com/research/btm2hg/sickle_cell
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Hematological Drugs
